General Virology encompasses the study of viruses, microscopic infectious agents that can cause a wide range of diseases in humans, animals, plants, and even bacteria. Some viruses also have an outer envelope derived from the host cell membrane. Virologists study various aspects of viruses, including their structure, replication, transmission, pathogenesis, and evolution. Understanding these fundamental aspects of virology is crucial for the development of vaccines to prevent viral infections.
Vaccines work by stimulating the body's immune system to recognize and respond to specific viral antigens, such as viral proteins or surface molecules. By mimicking natural infection without causing illness, vaccines prime the immune system to produce antibodies and memory cells that provide long-lasting protection against future encounters with the virus. There are several types of vaccines, including live attenuated vaccines, inactivated vaccines, subunit vaccines, recombinant vaccines, and nucleic acid vaccines. Each type of vaccine utilizes different strategies to present viral antigens to the immune system and induce a protective immune response.
Live attenuated vaccines contain weakened forms of the virus that can still replicate but cause minimal or no disease. Inactivated vaccines contain viruses that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are safe but may require booster doses to maintain immunity. Subunit vaccines contain purified viral antigens or protein subunits that stimulate an immune response. These vaccines are highly purified and do not contain live virus, making them safe for use in individuals with weakened immune systems. Recombinant vaccines are produced by genetically engineering viruses to express specific antigens. These vaccines are highly specific and can be tailored to target specific viral proteins or surface molecules. Examples include the recombinant hepatitis B vaccine and the recombinant subunit vaccine against COVID-19.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria